# Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

> **NCT00655824** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 124 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** ofatumumab

## Key facts

- **NCT ID:** NCT00655824
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01-01
- **Primary completion:** 2011-05-25
- **Final completion:** 2013-03-19
- **Target enrollment:** 124 (ACTUAL)
- **Why stopped:** The clinical development of intravenously administered ofatumumab in RA will no longer be pursued, so this study was prematurely terminated by the Sponsor.
- **Last updated:** 2017-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00655824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00655824, "Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00655824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*